 <h1>Lokelma Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>sodium zirconium cyclosilicate</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about sodium zirconium cyclosilicate. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Lokelma.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to sodium zirconium cyclosilicate: oral powder for suspension</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, sodium zirconium cyclosilicate (the active ingredient contained in Lokelma) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking sodium zirconium cyclosilicate:</p><p>
<i>More common</i>
</p><ul>
<li>Swelling</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Decreased urine</li>
<li>dry mouth</li>
<li>increased thirst</li>
<li>irregular heartbeat</li>
<li>loss of appetite</li>
<li>mood changes</li>
<li>muscle pain or cramps</li>
<li>nausea</li>
<li>numbness or tingling in the hands, feet, or lips</li>
<li>seizures</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<!-- end oral powder for suspension --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to sodium zirconium cyclosilicate: oral powder for reconstitution</i></p><h3>General</h3><p>The most commonly reported adverse reactions reported during clinical trials included edema and hypokalemia.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Edema (up to 16.1%)</p><p>During clinical trials, edema was reported in 4.4% of patients receiving 5 g/day, 5.9% of patients receiving 10 g/day and 16.1% of patients receiving 15 g/day for up to 28 days (placebo 2.4%).  In longer-term trials, 8% to 11% of patients receiving doses less than 15 g/day reported edema, generalized edema and peripheral edema.</p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hypokalemia</p>
<p><b>Frequency not reported</b>: Increase in sodium bicarbonate concentrations</p><p>In clinical trials, 4.1% of patients developed hypokalemia which resolved with dose reduction or discontinuation.  </p>
<p></p>
<p>Small, dose-dependent increases in sodium bicarbonate occurred with once daily dosing (1.1 mmol/L at 5 g/day; 2.3 mmol/L at 10 g/day; 2.6 mmol/L at 15 g/day; 0.6 mmol/L in placebo).  The clinical significance of this is unknown.</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Lokelma (sodium zirconium cyclosilicate)." Astra-Zeneca Pharmaceuticals, Wilmington, DE. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>How does the drug Lokelma work?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Lokelma (sodium zirconium cyclosilicate)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: cation exchange resins</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Lokelma &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Hyperkalemia</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to sodium zirconium cyclosilicate: oral powder for reconstitution</i></p><h3>General</h3><p>The most commonly reported adverse reactions reported during clinical trials included edema and hypokalemia.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Edema (up to 16.1%)</p><p>During clinical trials, edema was reported in 4.4% of patients receiving 5 g/day, 5.9% of patients receiving 10 g/day and 16.1% of patients receiving 15 g/day for up to 28 days (placebo 2.4%).  In longer-term trials, 8% to 11% of patients receiving doses less than 15 g/day reported edema, generalized edema and peripheral edema.</p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hypokalemia</p><p><b>Frequency not reported</b>: Increase in sodium bicarbonate concentrations</p><p>In clinical trials, 4.1% of patients developed hypokalemia which resolved with dose reduction or discontinuation.  </p><p></p><p>Small, dose-dependent increases in sodium bicarbonate occurred with once daily dosing (1.1 mmol/L at 5 g/day; 2.3 mmol/L at 10 g/day; 2.6 mmol/L at 15 g/day; 0.6 mmol/L in placebo).  The clinical significance of this is unknown.</p><p id="ref_1">1. "Product Information. Lokelma (sodium zirconium cyclosilicate)." Astra-Zeneca Pharmaceuticals, Wilmington, DE. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>How does the drug Lokelma work?</li>
</ul><h2>More about Lokelma (sodium zirconium cyclosilicate)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: cation exchange resins</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Lokelma &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Hyperkalemia</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>